Biomarin Pharmaceutical (BMRN) Debt Ratio (2012 - 2026)

Biomarin Pharmaceutical (BMRN) posted Debt Ratio of 0.17 for Q1 2026, up 111.71% on a QoQ basis from 0.08 in Q4 2025.

Biomarin Pharmaceutical (BMRN) Debt Ratio (2012 - 2026) Analysis & Trends

Biomarin Pharmaceutical's Debt Ratio history runs 14 years deep, the most recent figure standing at 0.17 for Q1 2026.

Quarterly Debt Ratio changed N/A year-over-year to 0.17 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.17 (changed N/A YoY) and the FY2025 annual result came in at 0.08, changed N/A from the prior year.
Debt Ratio was 0.17 for Q1 2026 at Biomarin Pharmaceutical, up from 0.08 in the prior quarter.
Across five years, Debt Ratio topped out at 0.17 in Q1 2026 and bottomed at 0.0 in Q4 2022.
A 5-year average of 0.05 and a median of 0.07 in 2024 frame the typical range for Debt Ratio.
Annual changes were most pronounced in 2022 — Debt Ratio tumbled 68.9% — and 2023, when it surged 2789.79%.
Biomarin Pharmaceutical's Debt Ratio stood at 0.0 in 2022, then jumped by 2789.79% to 0.07 in 2023, then retreated by 3.0% to 0.07 in 2024, then climbed by 12.31% to 0.08 in 2025, then jumped by 111.71% to 0.17 in 2026.
Business Quant data shows BMRN's Debt Ratio at 0.17 in Q1 2026, 0.08 in Q4 2025, and 0.07 in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	1.41
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	0.11
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	0.05
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Biomarin Pharmaceutical	11.33 Bn	9.11 Bn	571.21 Mn	0.17

Download Data